- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
China Supply Chain Progress Still Hampered by Corruption, Pollution, Working Conditions
Supply chains risks in China still include extremely high levels of corruption, environmental pollution issues and slow working conditions reforms, according to new analysis from Sedex.
Supply chains risks in China still include extremely high levels of corruption, environmental pollution issues and slow working conditions reforms, according to new analysis from Sedex.
While China remains “unparalleled in the region in terms of its productivity levels and speed at which deliveries can be turned around”, data from Sedex and global risk company Maplecroftpoint to continuing supply chain challenges such as health and safety issues, wages and working hours; inadequate storage and management of hazardous chemicals; and the sluggish progress of political liberalization.
“It is important that companies operating in the country understand the changing environment, with a growing middle class and changes in the availability of previously plentiful suppliers of cheap labor,” said Carmel Giblin, Sedex CEO. But the country’s main advantages remain its productivity levels and the speed at which deliveries can be turned around, which are “much, much better” than in countries such as Bangladesh and Cambodia, added Maplecroft’s Arvind Ramakrishnan.
Click here to download a copy of Sedex’s Responsible Sourcing Insights Briefings: China.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
